文献速递免疫规划传染病防控与疫情报告

可吸入表达M2e-FP的重组枯草芽孢杆菌孢子疫苗的构建及其在小鼠模型中对流感保护效力的评估

Construction of an inhalable recombinant M2e-FP-expressing Bacillus subtilis spores-based vaccine and evaluation of its protection efficacy against influenza in a mouse model.
PubMed 文献 · Vaccine · 2023-06-10

研究构建表达M2e-FP蛋白的重组枯草芽孢杆菌孢子疫苗(RSM2eFP),比较气雾经气管接种(i.t.)与灌胃(i.g.)免疫BALB/c小鼠的效力。i.t.途径对20×LD50 A/PR/8/34(H1N1)病毒攻击提供100%保护,i.g.仅50%;40×LD50攻击下i.t.仍提供80%保护。i.t.诱导更强肺黏膜和细胞免疫反应,并降低肺部感染性病毒产量,提示i.t.免疫可能是开发IAV黏膜疫苗的有前景策略。

要点

  • i.t.免疫RSM2eFP对20×LD50 H1N1攻击提供100%保护,i.g.仅50%。
  • 40×LD50攻击下i.t.免疫RSM2eFP仍提供80%保护。
  • i.t.较i.g.诱导更强肺黏膜免疫(IgG、SIgA)和细胞免疫反应。

核心结论

  • i.t.免疫RSM2eFP孢子疫苗可能是有前景的IAV黏膜疫苗开发策略。

研究设计与样本

  • 构建表达M2e-FP蛋白的重组枯草芽孢杆菌孢子疫苗(RSM2eFP),以气雾经气管接种(i.t.)或灌胃(i.g.)免疫BALB/c小鼠,评估效力。

主要发现

  • i.t.免疫对20×LD50 A/PR/8/34(H1N1)攻击提供100%保护,i.g.仅50%。
  • 40×LD50病毒攻击下i.t.免疫RSM2eFP提供80%保护。
  • i.t.较i.g.诱导更强肺黏膜免疫反应和细胞免疫反应,表现为IgG和SIgA高产。
  • i.t.免疫RSM2eFP降低小鼠肺部感染性病毒产量。

临床怎么用

  • 原文结论认为i.t.免疫RSM2eFP孢子疫苗可能是开发IAV黏膜疫苗的有前景策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Influenza A virus (IAV) is a deadly zoonotic pathogen that remains a burden to global health systems despite continuous vaccinations, indicating the need for an improved vaccine strategy. In this work, we constructed a new recombinant influenza vaccine using Bacillus subtilis spores expressing M2e-FP protein (RSM2eFP) and assessed its potency and efficacy in BALB/c mouse immunized via aerosolized intratracheal inoculation (i.t.) or intragastric (i.g.) administration. Immunization via i.t. route conferred 100 % protection against 20 × LD50 A/PR/8/34 (H1N1) virus compared with only 50 % via the i.g. route. Even when challenged with 40 × LD50 virus, the RSM2eFP vaccine immunized via i.t. provided 80 % protection. Consistently, i.t. inoculation of RSM2eFP spore vaccine induced a stronger lung mucosal immune response and a greater cellular immune response than i.g. administration, as indicated by the high production of IgG and SIgA. In addition, the RSM2eFP spore vaccine diminished the yield of infectious virus in the lung of mice immunized via i.t. These results suggest that i.t. immunization of the RSM2eFP spore vaccine may be a promising strategy for the development of mucosal vaccines against IAV infections.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ma D, Tian S, Qin Q, et al. Construction of an inhalable recombinant M2e-FP-expressing Bacillus subtilis spores-based vaccine and evaluation of its protection efficacy against influenza in a mouse model. Vaccine. 2023. PMID: 37308364. doi:10.1016/j.vaccine.2023.05.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。